- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-CEBPA
CEBPA Polyclonal Antibody for WB, IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, rat, souris et plus (3)
Applications
WB, IP, IF, IHC, chIP, ELISA
Conjugaison
Non conjugué
N° de cat : 18311-1-AP
Synonymes
Galerie de données de validation
Applications testées
Résultats positifs en WB | cellules L02, tissu hépatique humain |
Résultats positifs en IP | cellules L02 |
Dilution recommandée
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:1000 |
Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Applications publiées
KD/KO | See 3 publications below |
WB | See 52 publications below |
IHC | See 2 publications below |
IF | See 1 publications below |
ChIP | See 7 publications below |
Informations sur le produit
18311-1-AP cible CEBPA dans les applications de WB, IP, IF, IHC, chIP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris
Réactivité | Humain, rat, souris |
Réactivité citée | rat, Chèvre, Humain, porc, souris, Hamster |
Hôte / Isotype | Lapin / IgG |
Clonalité | Polyclonal |
Type | Anticorps |
Immunogène | Peptide |
Nom complet | CCAAT/enhancer binding protein (C/EBP), alpha |
Masse moléculaire calculée | 38 kDa |
Poids moléculaire observé | 40-45 kDa |
Numéro d’acquisition GenBank | BC160133 |
Symbole du gène | CEBPA |
Identification du gène (NCBI) | 1050 |
Conjugaison | Non conjugué |
Forme | Liquide |
Méthode de purification | Purification par affinité contre l'antigène |
Tampon de stockage | PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3 |
Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
CEBPA and its isoforms play important roles in lineage determination and gene activation in a variety of cell types by activating transcription from lineage-specific promoters. CEBPA is a DNA-binding protein that recognizes two different motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers. In hematopoiesis, C/EBPa is a key factor in driving the development of myeloid cells interacting with a variety of factors, including c-Myc, PU.1, and microRNAs. It can also form heterodimers with the related proteins CEBP-beta and CEBP-gamma. The encoded protein has been shown to bind to the promoter and modulate the expression of the gene encoding leptin which plays an important role in body weight homeostasis. CEBPA can interact with CDK2 and CDK4, thereby inhibiting these kinases and causing growth arrest in cultured cells. Several pathways have been implicated as the means by which CEBPA mediates cell cycle arrest and proliferation, including p21, cyclin-dependent kinases and the E2F complex via c-Myc. The calcualted molecular weight of CEBPA is 38 kDa, but modified CEBPA is about 42 kDa (PMID: 19623175).
Protocole
Product Specific Protocols | |
---|---|
WB protocol for CEBPA antibody 18311-1-AP | Download protocol |
IP protocol for CEBPA antibody 18311-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Cell Metab CircACC1 Regulates Assembly and Activation of AMPK Complex under Metabolic Stress.
| ||
Exp Mol Med Protective effect of hepatocyte-enriched lncRNA-Mir122hg by promoting hepatocyte proliferation in acute liver injury | ||
J Clin Invest Dysregulation of PI3K and hippo signaling pathways synergistically induces chronic pancreatitis via Ctgf upregulation. | ||
Bone Res mTORC1 induces plasma membrane depolarization and promotes preosteoblast senescence by regulating the sodium channel Scn1a. | ||
Theranostics PIWIL3/OIP5-AS1/miR-367-3p/CEBPA feedback loop regulates the biological behavior of glioma cells.
| ||
Leukemia Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells. |